There are currently 91 clinical trials in Winter Park, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Conquest Research, Shafran Gastroenterology Center, AdventHealth Winter Park and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
NCT06851858
Recruiting
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/12/2025
Locations: Research Site, Winter Park, Florida
Conditions: Endocrinology, Diabetes, Type II, Obesity
Register for Updates
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
NCT06293365
Recruiting
The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). A second cohort will be included... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/12/2025
Locations: Conquest Research, Winter Park, Florida
Conditions: Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Register for Updates
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
NCT05485961
Recruiting
This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: 84000426 - Florida Premier Research Institute, Winter Park, Florida
Conditions: Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
Register for Updates
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
NCT06812078
Recruiting
Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness o... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/09/2025
Locations: Takeda Site 14, Winter Park, Florida
Conditions: Idiopathic Hypersomnia
Register for Updates
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769
Recruiting
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
05/08/2025
Locations: Flourish Research - Orlando - PPDS, Winter Park, Florida
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374
Recruiting
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/07/2025
Locations: 89bio Clinical Study Site, Winter Park, Florida
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Register for Updates
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06132893
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/07/2025
Locations: Pediatrix Medical Group of Florida, Winter Park, Florida
Conditions: Focal Epilepsy
Register for Updates
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169
Recruiting
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis \[NASH\]).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/07/2025
Locations: 89bio Clinical Study Site, Winter Park, Florida
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Register for Updates
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
NCT04333576
Recruiting
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endomet... Read More
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
05/07/2025
Locations: Florida Premier Research Institute, LLC /ID# 224499, Winter Park, Florida
Conditions: Endometriosis
Register for Updates
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263
Recruiting
This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/06/2025
Locations: Research Site, Winter Park, Florida
Conditions: Asthma
Register for Updates
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
NCT04838301
Recruiting
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
05/06/2025
Locations: Conquest Research, Winter Park, Florida
Conditions: Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
Register for Updates
Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder
NCT05423717
Recruiting
This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to \< 18 years with insomnia disorder.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
05/05/2025
Locations: Florida Pediatric Research Institute, Winter Park, Florida
Conditions: Insomnia
Register for Updates